A

Agenus
D

AGEN

3.66000
USD
-0.15
(-3.94%)
مغلق
حجم التداول
39,143
الربح لكل سهم
-7
العائد الربحي
-
P/E
-0
حجم السوق
86,419,671
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    C
    CRVS
    0.20000
    (3.82%)
    5.44000 USD
    F
    FATE
    0.03000
    (2.28%)
    1.34500 USD
    G
    GNFT
    0.28000
    (8.31%)
    3.65000 USD
    O
    ONCY
    0.03500
    (4.19%)
    0.87090 USD
    P
    PRTA
    0.260
    (1.84%)
    14.370 USD
    V
    VYGR
    0.22000
    (4.21%)
    5.45000 USD
    المزيد
الأخبار
المقالات

العنوان: Agenus

القطاع: Healthcare
الصناعة: Biotechnology
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).